Physician profile
John Henegan
NPI 1114188471
$35,022.40
in general payments reported to CMS, 2019-2025
90 companies · $4,117 in 2025
The $4,117 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,207 · 2020: $842 · 2021: $4,185 · 2022: $11K · 2023: $10K · 2024: $2,814 · 2025: $4,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,599 · Consulting Fee: $7,362 · Travel and Lodging: $920 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,599.00 |
| Consulting Fee | $7,362.00 |
| Travel and Lodging | $919.80 |
| Education | $298.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $9,210.22 | 2019-2025 | |
| Genzyme Corporation | $8,076.42 | 2019-2025 | |
| Exelixis INC. | $4,669.29 | 2019-2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $1,572.12 | 2021-2025 | |
| Incyte Corporation | $866.31 | 2019-2025 | Jakafi, Monjuvi |
| Janssen Biotech, INC. | $859.70 | 2019-2025 | Tecvayli, Erleada, Darzalex |
| Novartis Pharmaceuticals Corporation | $668.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $601.26 | 2019-2025 | Lynparza, Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $572.24 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $527.88 | 2019-2025 | Vyloy, Xospata, Xtandi |
| Abbvie INC. | $454.16 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $444.39 | 2019-2025 | Iclusig, Ninlaro, Fruzaqla |
| Amgen INC. | $428.55 | 2019-2023 | Kanjinti, Lumakras |
| Gilead Sciences, INC. | $400.93 | 2022-2025 | Trodelvy |
| Celgene Corporation | $371.39 | 2019-2025 | Reblozyl, Opdualag, Opdivo |
Show all 89 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $334.89 | 2019-2025 | |
| Seagen INC. | $309.16 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $305.89 | 2019-2025 | Provenge |
| E.R. Squibb & Sons, L.L.C. | $297.80 | 2019-2025 | Opdivo |
| Daiichi Sankyo INC. | $152.09 | 2024-2025 | Injectafer, Vanflyta, Enhertu |
| Regeneron Healthcare Solutions, INC. | $151.06 | 2019-2025 | Libtayo, Lynozyfic |
| Genentech USA, INC. | $150.04 | 2019-2025 | Venclexta |
| Ipsen Biopharmaceuticals, INC | $132.80 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $131.35 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Karyopharm Therapeutics INC. | $127.47 | 2021-2025 | Xpovio |
| Emd Serono, INC. | $126.44 | 2021-2024 | Bavencio |
| Glaxosmithkline, LLC. | $124.37 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Alexion Pharmaceuticals, INC. | $113.78 | 2021-2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $106.39 | 2022-2025 | Givlaari |
| Adc Therapeutics America, INC. | $106.26 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.61 | 2019-2025 | |
| Beone Medicines USA, INC. | $101.36 | 2025 | Tevimbra, Brukinsa |
| Caris Mpi, INC. | $95.04 | 2025 | Mi Cancer Seek |
| Pharmaessentia USA Corporation | $92.59 | 2024-2025 | Besremi |
| Eisai INC. | $92.08 | 2019-2022 | |
| Beigene USA, INC. | $90.78 | 2021-2024 | Brukinsa, Tevimbra |
| Stemline Therapeutics INC. | $88.52 | 2024-2025 | Orserdu |
| Blueprint Medicines Corporation | $87.43 | 2022-2025 | Ayvakit |
| Coherus Oncology, INC. | $84.06 | 2023-2024 | |
| Springworks Therapeutics, INC. | $81.71 | 2024-2025 | Ogsiveo |
| Emmaus Medical, INC. | $73.79 | 2024-2025 | Endari |
| Verastem, INC. | $68.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.53 | 2020-2025 | Gilotrif |
| Sobi, INC | $66.97 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $63.98 | 2025 | Clonoseq |
| Servier Pharmaceuticals LLC | $61.96 | 2019-2025 | |
| Array Biopharma INC | $60.47 | 2024-2025 | Braftovi, Mektovi, Xalkori |
| Immunocore Limited | $57.55 | 2023-2024 | Kimmtrak |
| Jazz Pharmaceuticals INC. | $56.82 | 2020-2025 | |
| Secura Bio, INC. | $54.49 | 2019-2022 | |
| Eusa Pharma (US) LLC | $52.46 | 2019-2020 | |
| Geron Corporation | $51.60 | 2025 | Rytelo |
| Dova Pharmaceuticals | $50.79 | 2021 | |
| Recordati_rare_diseases_inc. | $49.42 | 2023-2024 | Sylvant, Panhematin |
| Morphosys, US INC. | $48.58 | 2021-2023 | Monjuvi |
| Novo Nordisk INC | $45.98 | 2024-2025 | Esperoct |
| Lilly USA, LLC | $45.40 | 2019-2025 | Jaypirca, Retevmo, Verzenio |
| Pharmacyclics LLC, An Abbvie Company | $41.66 | 2019-2023 | Imbruvica, Epkinly |
| Sanofi US Services INC. | $40.22 | 2025 | |
| Agios Pharmaceuticals, INC. | $39.99 | 2025 | Pyrukynd |
| Genmab U.S., INC. | $38.81 | 2023-2025 | Tivdak, Epkinly |
| G1 Therapeutics, INC. | $35.98 | 2023 | Cosela |
| Janssen Scientific Affairs, LLC | $35.61 | 2020 | |
| Pharmacosmos Therapeutics INC. | $34.46 | 2024 | Cosela |
| Tolmar, INC. | $30.12 | 2023-2025 | Jatenzo, Eligard |
| Helsinn Therapeutics (U.S.), INC. | $28.10 | 2020 | |
| Puma Biotechnology, INC. | $27.89 | 2019-2023 | |
| Tesaro, INC. | $27.37 | 2019 | |
| Kyowa Kirin, INC. | $25.41 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $24.20 | 2019 | |
| Hema Biologics, LLC | $23.57 | 2024 | Sevenfact |
| Myovant Sciences INC. | $20.03 | 2021 | |
| Blue Earth Diagnostics | $19.02 | 2023 | |
| Janssen Pharmaceuticals, INC | $18.27 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $16.63 | 2021 | |
| Legend Biotech USA INC. | $16.37 | 2025 | Carvykti |
| Bard Peripheral Vascular, INC. | $16.16 | 2024 | Trek |
| Azurity Pharmaceuticals, INC. | $16.08 | 2024 | Vivimusta |
| Deciphera Pharmaceuticals INC. | $15.69 | 2022 | |
| Csl Behring | $15.63 | 2019 | |
| Becton, Dickinson and Company | $15.21 | 2022 | |
| Taiho Oncology, INC. | $14.52 | 2022 | |
| Kite Pharma, INC. | $14.40 | 2023 | Yescarta |
| Clovis Oncology, INC. | $14.26 | 2019 | |
| Acrotech Biopharma INC. | $13.83 | 2024 | Beleodaq |
| Mirati Therapeutics, INC. | $13.76 | 2023 | Krazati |
| Apellis Pharmaceuticals, INC. | $13.36 | 2022 | |
| Akcea Therapeutics, INC. | $13.09 | 2020 | |
| Tersera Therapeutics LLC | $12.11 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Orgovyx $8,707Cabometyx $446Lynparza $368Jakafi $358Iclusig $354Monjuvi $317Keytruda $310Epkinly $287Padcev $252Xtandi $246Imfinzi $195Tecvayli $184Reblozyl $180Sarclisa $180Venclexta $164Imbruvica $161Talzenna $156Kisqali $154Provenge $139Vyloy $134Jevtana $131Opdivo $120Elahere $112Kanjinti $109Lumakras $109Tavalisse $101Rezlidhia $101Pluvicto $100Welireg $99.21Ultomiris $97.22Mi Cancer Seek $95.04Besremi $92.59Erleada $91.21Givlaari $89.89Xpovio $89.52Orserdu $88.52Darzalex $87.44Talvey $86.14Udenyca $84.06Rybrevant $83.52Brukinsa $82.98Ogsiveo $81.71Trodelvy $80.77Fabhalta $76.57Tevimbra $74.37Gavreto $74.17Endari $73.79Fotivda $72.12Ayvakit $70.76Cosela $70.44Libtayo $70.37Injectafer $68.05Doptelet $66.97Vanflyta $66.85Xospata $65.18Inlyta $64.46Clonoseq $63.98Enhertu $62.98Balversa $62.16Akeega $62.16Braftovi $60.47Mektovi $60.47Scemblix $60.31Zynlonta $59.44Kimmtrak $57.55Vitrakvi $57.48Nubeqa $57.48Stivarga $57.48Rytelo $51.60Bavencio $49.02Rezurock $48.71Lynozyfic $45.47Tukysa $44.92Jemperli $42.28Zejula $42.28Zepzelca $41.54Pyrukynd $39.99Cresemba $39.11Opdualag $38.71Lutathera $38.07Ojjaara $35.49Cablivi $35.47Lorbrena $33.02Xalkori $33.02Paxlovid $32.65Comirnaty $32.65Sylvant $31.52Eligard $30.12Sevenfact $23.57Esperoct $23.13Tivdak $22.23Ninlaro $21.76Fruzaqla $19.76Axumin $19.02Jaypirca $18.43Verzenio $18.43Retevmo $18.43Panhematin $17.90Ibrance $17.47Carvykti $16.37
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Henegan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.